In this study, we explored the effect of CDK8/19 inhibition on OC tumor growth, disease progression, and chemotherapeutic response, showing for the first time that the use of a CDK8/19i, especially in combination with platinum-based therapy, is clinically translatable for gynecological cancers. This evidence concerns the gene CDK8 and neoplasm.